314, T. V. Indusstrial Estate, S.K. Ahire Marg,

Worli, Mumbai - 400 030. India Tel.: + 91 22 6663 5456

Fax: +91 22 6663 5460 E-mail: auro@aurolabs.com Web: www.aurolabs.com

Reg. Off. / Mfg. Unit: K-56, M. I. D. C. Tarapur, Dist. Palghar, Maharashtra - 401506. CIN No. L33125MH1989PLC051910

Date: February 11, 2021

To BSE Limited, Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

Reg: Security Code No. 530233:

Sub: Outcome of the Board Meeting dated February 11, 2021

Dear Sir / Ma'am,

Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015 ("SEBI Listing Regulations), we wish to inform you that the Board of Directors at their Meeting held today (i.e. **Thursday**, **February 11**, **2021**), inter-alia, considered following matters:

1. Approved Un-audited Financial results for the quarter ended December 31, 2020 as recommended by Audit Committee alongwith the Limited Review Report.

In this regard, we are enclosing herewith:

- ➤ Unaudited Financial Results for the quarter ended December 31, 2020.
- ➤ Limited Review Report received from the Statutory Auditor of the Company.
- 2. Approved the Notice of Postal Ballot

The Board approved the Notice of Postal Ballot dated February 11, 2021 regarding the following matters:

- a. Appointment of Mrs. Kavita Sharma as an Independent Director of the Company w.e.f. February 11, 2021 for five consecutive years (i.e. from February 11, 2021 to February 10, 2026) subject to approval of the members through evoting to be conducted by the Postal Ballot. She is not related to any of the Director / Key Managerial Personnel of the Company.
- b. On recommendation of the Nomination & Remuneration Committee, pursuant to Regulation 17(6)(e) of SEBI (Listing Obligations and Disclosure Requirement), 2015 the Board approved for the continuation of payment

remuneration to Executive Directors for their balance terms, in excess of the threshold limit as specified in SEBI Listing Regulations, to Mr. Sharat Deorah, Chairman and Managing Director & Mr. Siddhartha Deorah, Whole time Director of the Company considering their valuable contributions in the growth of the Company subject to the approval by the shareholders through evoting by Postal Ballot.

The Meeting of the Board commenced at 4.05 p.m. and concluded at 4.50 p.m. The results will be published in the newspaper pursuant to Regulation 47(1) (b) of SEBI (LODR) Regulations, 2015 in due course.

Kindly take the same on record and acknowledge.

Thanking You,

Yours Faithfully, For AURO LABORATORIES LIMITED

MULWW

SIDDHARTHA DEORAH WHOLE TIME DIRECTOR [DIN: 00230796]

Encl.: as above

## AURO LABORATORIES LIMITED CIN NO. :- L33125MH1989PLC051910

Regd. Office: K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR BOISAR, DIST. PALGHAR 401506, MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com

## ANNEXURE - I

	T - I STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QU	ARTER AND NI	NE MONTH END	ED 31ST DECE	MBER 2020	(110.	In Lakhs)
		3 Months ended	Preceding 3 Months ended	3 Months ended	Nine months Ended		For the Year Ended
Sr.		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
No.	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
_							
1_	Income from Operations						
	(a) Net Sales/Income from Operations (Net)	1,310.90	1,535.36	954.4	4,068.72	3,436.23	4,379.0
2	Other Income	25.05	27.87	10.76	58.61	59.07	97.2
3	Total Revenue (1 + 2)	1,335.95	1,563.23	965.16	4,127.33	3,495.30	4,476.3
4	Expenses						
	a. Consumption of raw material	609.89	877.65	350.35	2,224.73	1,974.51	2,342.2
	b. Purchase of Stock-in-trade	0.00	19.20	-	20.43	25.75	56.6
	c. (Increase) / decrease in Finished Goods stock	13.5	0.26	95.32	14.66	(70.79)	49.1
	in trade and work in progress		7.20		30	(, , , , , ,	1
	d. Employee benefits expense	157.34	140.29	136.68	423.83	342.63	527.5
	e. Finance Cost	4.88	7.95	9.82	20.80	36.79	46.6
	f. Depreciation and amortisation expenses	26.00	25.00	28.00	76.00	79.00	102.3
	g. Other Expenses	243.96	181.98	213.6	564.40	620.26	787.6
	Total Expenses (4)	1,055.57	1,252.33	833.77	3,344.85	3,008.15	3,912.14
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 + 4)	280.38	310.90	131.39	782.48	487.15	564.18
6	Exceptional items				-	-	
7	Profit / (Loss) before extraordinary items and tax (5 ± 6)	280.38	310.90	131.39	782.48	487.15	564.1
8	Extraordinary items			-	-	-	
9	Profit / (Loss) before tax (7 ± 8)	280.38	310.90	131.39	782.48	487.15	564.1
10	Tax expense			-	-	_	
	(a) Current tax expesnes for current year	77.10	85.50	27.55	215.18	128.36	152.4
	(b) MAT credit (where applicable)				-		1
	(c) Defferered tax			_	-	-	6.2
11	Profit / (Loss) for the period from continuing operation (9± 10)	203.28	225.40	103.84	567.30	358.79	405.4
12	Profit / (Loss) for discontinuing operations			_	-	-	
13	Tax expense of discontinuing operations			-	-		
14	Profit / (Loss) for discontinuing operation (after tax) (12 ± 13)	203.28	225.40	103.84	567.30	358.79	405.4
15	Other Comprehensive Income	7.89	(1.12)	25.16	7.89	25.16	11.2
16	Total Comprehensive Income for the period (14 ± 15)	211.17	224.28	129.00	575.19	383.95	416.6
	Paid-up equity share capital	623.25	623.25	623.25	623.25	623.25	623.2
	(Face value of Rs. 10 each)						
17	Reserves excluding Revaluation Reserves as			-	-	-	1,526.5
18	per balance sheet of previous accounting year) Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):		-				
10	· • • • • • • • • • • • • • • • • • • •	3.00	2.00	4.67	0.40	5.70	
	(a) Basic	3.26	3.62	1.67	9.10	5.76	6.5
	(b) Diluted	3.26	3.62	1.67	9.10	5.76	6.5

## Notes:

- The above unaudtied financial results for the quarter ended 31st December, 2020 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on 11th February 2021.
- The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- 3) Limited review has been carried out by the Statutory Auditors of the Company.

FOR & BEHALF OF BOARD OF DIRECTORS

AURO LABORATORIES LIMITED

SIDDHARTHA DEORAH WHOLE TIME DIRECTOR DIN NO. 00230796

Place : Mumbai Date : 11/02/2021





To,
The Board of Directors,
Auro Laboratories Limited.

We have reviewed the standalone Ind AS financial results of Auro Laboratories Ltd. ("the company") for the Quarter ended December 31, 2020, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016.

This Statement is the responsibility of the Company's Management and had been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements prepared in accordance with generally accepted accounting standards in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khurdia Jain & Co.

Chartered Accountants

Regd. No. 120263 W

ZERED ACC

Sampat Khurdia

**Partner** 

Membership No. 033615 Firm Reg. No. 120263W

Place: Mumbai

Date: 11<sup>th</sup> February, 2021 UDIN: 21033615AAAACC3964